Literature DB >> 6952952

Response of acute myelomonocytic leukemia to alkyl-lysophospholipids. A case report.

W E Berdel, U Fink, P A Maubach, B Permanetter, J Rastetter.   

Abstract

Acute myelomonocytic leukemia refractory to treatment with daunomycin, cytosin arabinoside and thioguanine morphologically and clinically responded twice to therapy with alkyl-lysophospholipids (ALP). Beginning 48 h after treatment leukemic cells developed large vacuoles in cytoplasm and nucleus which disrupted the continuity of the cell membranes. Normal hematopoietic cells remained morphologically unchanged. Within 14 days of first ALP treatment leukemic cells in peripheral blood were reduced to less than 10%, but normal hematopoiesis recovered under therapy with an increase of granulocytes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6952952     DOI: 10.1007/bf00320765

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  13 in total

1.  [Concerning the synthesis of lysolecithin and its ether analogs].

Authors:  D Arnold; H U Weltzien; O Westphal
Journal:  Justus Liebigs Ann Chem       Date:  1967

2.  [O-methylated and O-acetylated lysolecithin].

Authors:  H U Weltzien; O Westphal
Journal:  Justus Liebigs Ann Chem       Date:  1967

3.  The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma.

Authors:  W E Berdel; W R Bausert; H U Weltzien; M L Modolell; K H Widmann; P G Munder
Journal:  Eur J Cancer       Date:  1980-09       Impact factor: 9.162

4.  Growth inhibition of malignant hypernephroma cells by autologous lysophospholipid incubated macrophages obtained by a new method.

Authors:  W E Berdel; U Fink; B Egger; A Reichert; P G Munder; J Rastetter
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

5.  Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids.

Authors:  R Andreesen; M Modolell; P G Munder
Journal:  Blood       Date:  1979-08       Impact factor: 22.113

Review 6.  Anti-tumor action of alkyl-lysophospholipids (Review).

Authors:  W E Berdel; W R Bausert; U Fink; J Rastetter; P G Munder
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

7.  Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids.

Authors:  M Modolell; R Andreesen; W Pahlke; U Brugger; P G Munder
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

8.  Inhibition by alkyl-lysophospholipids of tritiated thymidine uptake in cells of human malignant urologic tumors.

Authors:  W E Berdel; U Fink; B Egger; A Reichert; P G Munder; J Rastetter
Journal:  J Natl Cancer Inst       Date:  1981-05       Impact factor: 13.506

9.  The effects of alkyl-lysophospholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines, HL60 and K562.

Authors:  T Tidwell; G Guzman; W R Vogler
Journal:  Blood       Date:  1981-04       Impact factor: 22.113

10.  Alkyl-lysophospholipids inhibit the growth of hypernephroid carcinomas in vitro.

Authors:  W E Berdel; U Fink; B Egger; A Reichert; P G Munder; J Rastetter
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

View more
  1 in total

1.  Antineoplastic activity of synthetic lysophospholipid analogs.

Authors:  W E Berdel
Journal:  Blut       Date:  1982-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.